Clinical Cancer Research Bridging the Lab and the Clinic in Cancer Medicine
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online
This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Homann, N.
Right arrow Articles by Bosch, F. X.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Homann, N.
Right arrow Articles by Bosch, F. X.
Clinical Cancer Research Vol. 7, 290-296, February 2001
© 2001 American Association for Cancer Research

Molecular Oncology, Markers, Clinical Correlates

Overexpression of p53 in Tumor-distant Epithelia of Head and Neck Cancer Patients Is Associated with an Increased Incidence of Second Primary Carcinoma1

Nils Homann, Matthias Nees, Christian Conradt, Andreas Dietz, Hagen Weidauer, Heinz Maier and Franz X. Bosch2

Molekularbiologisches Labor, Universitäts-HNO-Klinik Heidelberg [N. H., M. N., A. D., H. W., F. X. B.], HNO-Klinik, Bundeswehrkrankenhaus Ulm [H. M.], Zentrum für Medizinische Biometrie und Informatik, Universität Heidelberg [C. C.], D-69120, Heidelberg, Germany


   ABSTRACT
Top
 ABSTRACT
INTRODUCTION
 PATIENTS AND METHODS
 RESULTS
 DISCUSSION
 REFERENCES
 
Second primary carcinoma is a peculiar feature of head and neck cancer and represents a form of treatment failure distinct from the recurrence of the primary tumor. Whether altered p53 expression in tumor-distant epithelia at the time of diagnosis is of clinical value as a biomarker for second primary carcinoma development has not been rigorously answered because of the lack of long-term follow-up studies involving a sufficiently large patient cohort. In this prospective study, we have investigated p53 expression in tumor-distant epithelia and in the corresponding primary tumors of 105 head and neck cancer patients by immunohistochemistry on frozen sections. After a median follow-up of 55 months, the clinical course of disease parameters, i.e., local recurrences, lymph node and distant metastasis, incidence of second primary carcinoma, and survival, was evaluated. Overexpression of p53 in tumor-distant epithelia was found in 49 patients (46.7%), and it was independent of the p53 protein status of the primary tumor and of the tumor site, size, stage, and grading. Mucosal p53 overexpression was not associated with local primary recurrences, lymph node or distant metastases, or overall survival. Importantly, mucosal p53 overexpression, but not overexpression in the primary tumors, was significantly associated with an increased incidence of second primary carcinomas (P = 0.0001; Fisher’s exact test). When the times to second primary tumor occurrence were analyzed by the Kaplan-Meier method, the difference remained significant (P = 0.005; log rank test). We conclude that IHC staining for p53 overexpression in tumor-distant epithelia provides a simple and rapid tool to identify head and neck cancer patients at increased risk of developing second primary tumors. Because p53 overexpression in these epithelia in our patient cohort was specifically associated with second primary cancer but not with recurrences, at least a fraction of the second primary cancers appears to have resulted from genetic events in the mucosa ("field cancerization").


   INTRODUCTION
Top
 ABSTRACT
 INTRODUCTION
PATIENTS AND METHODS
 RESULTS
 DISCUSSION
 REFERENCES
 
SCC3 of the head and neck is the sixth most common malignancy in the world, and the 5-year survival rate is one of the lowest among all cancers (1) . Accumulation of mutations in oncogenes and tumor suppressor genes is a major molecular mechanism of tumor development (2) . Among the tumor suppressor genes, inactivation of the p53 gene is one of the most frequent events (3) . Overexpression of the p53 protein is frequently but not always associated with gene mutation and is regarded to be a promising candidate that might predict patient prognosis (4) . Taking recent publications together, there is now good evidence for a prognostic impact of p53 mutations in head and neck cancer, i.e., they seem to be associated with an increased risk of locoregional treatment failure (5 , 6) . p53 DNA contact mutations appear to harbor a distinctly high malignant potential and to predict a poorer survival (7) . Regarding p53 overexpression, Shin et al. (8) , in their cohort of 69 patients with definitive local therapy (46% were stage I and II tumors), demonstrated a predictive value of p53 overexpression for shorter survival. However, other studies failed to confirm these results or revealed contradictory results (9, 10, 11, 12, 13) .

p53 overexpression not only occurs in 23–70% of all head and neck tumors (4) but also has commonly been found in dysplastic and nondysplastic premalignant epithelial lesions (9 , 14, 15, 16, 17, 18) . Even less is known about the clinical value of the observed p53 overexpression in these epithelia. Uhlmann et al. (15) performed a retrospective study on laryngeal cancer patients who previously underwent laryngeal biopsies without the diagnosis of cancer. Linear basal overexpression of p53 in premalignant lesions was found to be significantly associated with an increased risk of progression to cancer (15) . In a prospective study, Gallo et al. (16) have reported that simultaneous p53 and p16INK4a alterations in premalignant laryngeal lesions have prognostic relevance in the progression to a malignant tumor. Thus, in the case of laryngeal precursor lesions, p53-overexpressing cells seem to have some malignant potential. In oral premalignant lesions, the predictive power of p53 overexpression appeared even less pronounced than in laryngeal lesions. Ogden et al. (17) have noted that p53 overexpression does not necessarily predict further malignant disease. Taking these studies together, it is clear that p53 overexpression will not turn out to be a definitive biomarker (indicating 100% risk) for second primary carcinoma (reviewed in Ref. 18 ). Whether p53 overexpression has reasonable predictive power at all has not been rigorously answered. For answering this question, long-term follow-up studies are required. For instance, on the basis of an actuarial rate of second primary cancer of 10% and on an 3-fold increase of this rate in a patient group with p53-positive, tumor-distant epithelia, a cohort size of 50 patients will only provide a study power of 50%. Therefore, the literature does not contain a study with a sufficiently large number of patients to answer this question.

We have shown previously that in multiple anatomical sites within one cancer patient, histologically normal appearing tumor-distant epithelial cells can be found that express a mutated p53 protein (19) . This finding, which was confirmed by Waridel et al. (20) , has provided a possible molecular basis for the development of second (multiple) primary carcinomas.

Here, we present a prospective long-term follow-up study involving 105 patients (including 15 patients from our previous work) with malignant head and neck tumors. We have focused on the analysis of p53 protein expression in tumor-distant epithelia at the time of surgery of the primary tumor and have compared this with clinicopathological parameters, including the occurrence of second primary carcinoma. Immunohistochemical staining of tissue sections is a simple, rapid, and reliable method to assess p53 protein expression and can be performed according to standard protocols in many clinical laboratories. The size of our patient cohort was estimated to be sufficiently large to answer whether p53 overexpression is associated with second primary carcinomas.

Our results show that it is indeed possible, using this simple assay, to identify patients with higher and lower risk for second primary SCCs of the head and neck.


   PATIENTS AND METHODS
Top
 ABSTRACT
 INTRODUCTION
 PATIENTS AND METHODS
RESULTS
 DISCUSSION
 REFERENCES
 
Patients and Tissue Samples.
Clinicopathological parameters from patients with head and neck cancer were obtained from patient records and the statements of the pathology department. Only patients from whom fresh-frozen biopsies could be obtained and who were regularly seen at follow-up examinations were recruited. The enrollment period started from May 1990 and ended in December 1998. Inclusion criteria were SCC only (excluding skin cancer) and patients presenting with primary tumors (excluding patients with recurrent tumors and patients with secondary tumors who had been treated with radiation and/or chemotherapy) at the Department of Oto-Rhino-Laryngology of the University of Heidelberg. Accuracy of the clinical data was validated by two independently reviewing investigators, who were unaware of the results of p53 staining. The data collected included age, gender, primary tumor site (oral cavity, oropharynx, larynx, hypopharynx, or other), tumor size (T1–4), lymph nodal status (N0–3), American Joint Committee on Cancer Stage (stages I–IV), histological grading (well, moderately, poorly, and undifferentiated), and cause of death. In follow-up, recurrences of primary tumor and occurrences of lymph node metastases, distant metastases, and second primary tumors were recorded. For the diagnosis of second primary tumors, a modification of the criteria of Warren and Gates was used (see Ref. 21 ). Only second primary tumors occurring in the aerodigestive tract were enrolled in this study.

All tissues were collected during the operation and immediately snap-frozen in 2-methyl-butane, precooled in liquid nitrogen, and stored until use at -80 C. One hundred fifty-one snap-frozen, tumor-distant epithelial tissues were available for study. Precise information on the anatomical location was available in 113 cases (the other biopsies were merely classified as tumor-distant). The tumor-distant epithelia were derived from the site adjacent to the tumor (e.g., oropharyngeal mucosa in case of a larynx carcinoma and hypopharyngeal mucosa in case of an oropharynx carcinoma) or from the contralateral subsite in case of oral cavity and larynx tumors (see Table 2Citation ). These small biopsies had a minimum distance of 4 cm to the margin of the tumor and were histopathologically tumor free. Epithelia of 63 patients who underwent operation for other reasons than malignancy were collected for comparison.


View this table:
[in this window]
[in a new window]
  		Table 2 p53 expression in normal and mildly dysplastic epithelia in patients with and without malignancy in the head and neck region, and sites of expression

 
Immunohistochemistry.
Immunohistochemical staining of the frozen sections with p53-antibody Bp53-12 (Progen, Heidelberg, Germany) was performed as described earlier (19) . Tissues were ranked as p53 positive if parabasal cell clusters or a continuous cell nest of more than five cells with a strong nuclear staining were seen. Faint cytoplasmic or nuclear staining not meeting the former criteria and all other tissues were ranked as p53 negative. In case of availability of several tissues from one patient, one positive epithelium was enough to rank the patient as p53 positive for tumor-distant epithelia.

Statistical Analysis.
The major statistical endpoints of this study were the incidence and the time to diagnosis of posttherapeutic events during follow-up, in particular local recurrence from primary carcinoma or second primary carcinoma, in relation to the p53 expression status in tumor-distant epithelia or primary tumors, respectively. Events of tumor relapse were calculated from the date of initial therapy. Calculations were performed by using Fisher’s exact test or unpaired Students t test (GraphPad version 2.02; InStat Software) for univariate analyses. P < 0.05 was regarded as significant. All Ps are expressed as mean ± 1 SD. The Kaplan-Meier method was used to compare the incidence and time course of tumor relapse events between groups with p53 positivity and p53 negativity. Differences were quantitated and evaluated for significance using the log-rank test stratified for tumor site.

The study was approved in accordance with the declarations of Helsinki.


   RESULTS
Top
 ABSTRACT
 INTRODUCTION
 PATIENTS AND METHODS
 RESULTS
DISCUSSION
 REFERENCES
 
One hundred five patients met the inclusion criteria. The p53 expression status in the primary tumors and in the tumor-distant epithelia of these patients and the main clinical characteristics are summarized in Table 1Citation . Forty-nine cancer patients (46.7%) revealed p53-positive epithelia, whereas no p53 positivity could be detected in epithelia obtained from 63 noncancer patients. Examples of p53 positivity in frozen sections of tumor-distant epithelia are presented in Fig. 1Citation . The pattern seen in Fig. 1Citation a, i.e., two parabasally located small clusters of stained cells, represents the threshold positivity. Fig. 1Citation b shows the staining pattern most often encountered in tumor-distant mucosa, i.e., staining of basal and parabasal cells. The positive staining in Fig. 1Citation c extended from the basal-most layer into the first suprabasal layers. This pattern was reported to be predictive for second primary cancer (22) . For comparison, Fig. 1Citation d shows the transition from negative to positive in close proximity of a SCC. p53 expression in the epithelia did not correlate with the p53 protein status of the primary tumor; neither did it correlate with tumor size, tumor stage, nodal status, or histological grading. Regarding smoking habits, there was an insignificant difference between the two groups. Smoking habits remained balanced between the groups during follow-up. Because this study focused primarily on the question of a predictive role of the p53 protein status in tumor-distant mucosa at the time of presentation with the primary tumor, we did not attempt to obtain detailed information about tobacco consumption. The follow-up period ranged from 5 to 106 months, with a mean time of 55 months. The median occurrence of tumor-dependent events was 9.9 ± 6.2 months (mean ± 1 SD) for primary recurrences (n = 20), 42.8 ± 26 months for second primary tumors (n = 15), 25.5 ± 25.3 months for lymph node metastases (n = 20), and 15.5 ± 11.7 months for distant metastases (n = 24). Forty-two patients died during the follow-up period. Death rate, the occurrence of new lymph node and distant metastases, and recurrences of the primary tumor were not associated with p53 overexpression in the epithelia. However, the rate of second primary tumors in the aerodigestive tract was significantly higher in patients whose epithelia showed p53 overexpression (14 versus 1 in the p53-negative group). Table 2Citation demonstrates that p53-positive cell clusters were seen more frequently in epithelia of the hypopharynx than in the oropharynx, oral cavity, or larynx; this difference was, however, not significant. Within anatomical subgroups of the larynx, p53 overexpression was significantly more frequent in supraglottic and glottic regions than in the subglottis. Fig. 2Citation A shows that Kaplan-Meier analyses and log-rank tests confirmed the significant association between p53 overexpression specifically in the epithelia and second primary malignancy. The same analysis confirmed the lack of such a correlation of p53 overexpression in the epithelia with local recurrences from the primary tumors (Fig. 2Citation B). There was also no significant influence of mucosal p53 overexpression with disease-free and overall survival (not shown). Importantly, we could not find a correlation between the p53 status in the primary tumors and the incidence of second primary tumors (Fig. 2Citation C). This latter result was confirmed either when a larger cohort of 250 patients including the 105 patients of this study was analyzed or when those patients were analyzed separately, of whom no tumor-distant mucosal biopsies were available (not shown). The anatomical site of the second primary tumors did not significantly correlate with the sites from where the mucosal biopsies analyzed had been taken (not shown).


View this table:
[in this window]
[in a new window]
  		Table 1 Characteristics of the patients of the study

In some cases, collected data were insufficiently recorded, which led to a lack of information in some groups. For smoking and drinking habits, only patients who had participated in another case-control study to evaluate possible risk factors for head and neck cancer were included.

 


View larger version (156K):
[in this window]
[in a new window]
  		Fig. 1. Patterns of p53 expression in frozen sections of tumor-distant mucosal biopsies (immunohistochemistry with Bp53-12 monoclonal antibody. a, two parabasally located small clusters of stained cells in epithelium from the ventricular fold, defined as threshold positivity; b, basal and parabasal staining in hypopharyngeal mucosa; c, strongly positive staining extending into suprabasal layers in hypopharyngeal mucosa; d, for comparison, staining at the transition from mucosa to p53-positive SCC.

 


View larger version (14K):
[in this window]
[in a new window]
  		Fig. 2. A, incidence and time course of occurrence of second primary carcinomas in relation to the p53 expression status in tumor-surrounding epithelia. Comparison by the Kaplan-Meier method. The median time of occurrence of second primary tumors was 42.8 months; the single case in the p53-negative group occurred after 54 months. Stratified log-rank test revealed a significant difference between the groups (P = 0.0059). B, incidence and time course of occurrence of local recurrences from the primary tumors in relation to the p53 expression status in tumor-surrounding epithelia. Comparison by the Kaplan-Meier method. The incidence of primary recurrences was insignificantly higher in the p53-negative group (P = 0.2765; stratified log-rank test). C, second primary carcinomas in relation to the p53 expression status of the primary tumors. Eighty-nine primary tumors were analyzed by the Kaplan-Meier method. Fifty tumors were p53 positive, but the number of second primary tumors was the same in the two groups (n = 5 each). Thus, the p53 protein status in the primary tumor did not correlate with second primary cancer. p53sh = 0, p53 negative; p53sh = 1, p53-positive mucosa.

 

   DISCUSSION
Top
 ABSTRACT
 INTRODUCTION
 PATIENTS AND METHODS
 RESULTS
 DISCUSSION
REFERENCES
 
The prognosis of head and neck cancer patients with definitive locoregional tumor treatment is influenced by a peculiar characteristic of this cancer type–the frequent incidence of second primary tumors (21) . In the present study, we have used immunohistochemistry and long-term follow-up on a sufficiently large number of cases to examine whether the frequently observed overexpression of p53 in tumor-distant epithelia of head and neck cancer patients (14, 15, 16, 17, 18) could be a biomarker with predictive value for second primary cancer. We show that overexpression of p53 in tumor-distant epithelia was associated with an increased incidence of second primary carcinoma (Table 1Citation ; Fig. 2Citation ). At the same time, as shown in Table 1Citation and Fig. 2Citation C, the data provide strong evidence against a correlation between the p53 protein status in the primary tumor and the occurrence of second primary tumors. This is in contrast to the study by Shin et al. (8) , who have described a weak association between p53 overexpression in the tumor and the rate of second primary carcinoma. In another large cohort of ~145 head and neck cancer patients in which no tumor-distant mucosal biopsies were available, we also did not obtain any evidence for an association of p53 overexpression in the primary SCCs and the rate of second primary carcinoma (data not shown).

This is, to our knowledge, the first study of a sufficiently large-scale providing evidence that p53 overexpression in tumor-distant mucosa of head and neck cancer patients indicates an increased predisposition or susceptibility of the mucosa of these patients to progression to a second malignant tumor. We have gathered several arguments to support this notion: (a) as a consequence of using frozen sections rather than paraffin sections, we noted that p53 positivity was extremely specific for tumor-distant epithelia of cancer patients (Table 2)Citation . In contrast, staining of paraffin sections after antigen retrieval has a much lower specificity for malignancy or premalignancy because p53 positivity is also found in benign epithelial lesions (23) and in mucosal biopsies from healthy individuals (24) . In the latter study, van Oijen et al. (26) found that smoking increased the frequency of p53 overexpression among cancer patients but not among healthy individuals. In our cohort, the incidence of p53 overexpression was also higher in the smoking group, but the difference was not statistically significant (Table 1)Citation ; (b) because these epithelia were picked at random, either from the adjacent anatomical site or from the contralateral subsite, they represent an undefined entity (in contrast to leukoplakias, for example), in line with a prospective study design. This makes confounders unlikely to occur; (c) the second primary tumors occurred much later than the local recurrences from primary tumors (9.9 ± 6.2 months for primary recurrences and 42.8 ± 26 months for second primary tumors). This difference in the time interval to presentation with secondary cancer is regarded to be crucial for the discrimination between second primary and local recurrence, although in individual cases discrimination may be difficult. Jones et al. (21) in a large retrospective study found an actuarial second primary rate of 9.1% and a median time to presentation of 36 months. Our data therefore indicate that the second primaries have originated independently from the local recurrences. This is in line with previous findings by Chung et al. (25) and van Oijen et al. (26) , who showed discordant p53 gene mutations in primary and second primary cancers and with discordant p53 gene mutations in primary tumor and tumor-distant mucosa (19 , 20) ; (d) it is noteworthy that the anatomical distribution of p53 positivity correlated well with the tumor site distribution. In the larynx, only supraglottic and glottic regions but not subglottic regions showed p53 overexpression. This is interesting, because subglottic tumors are very seldom seen; and (e) most importantly, we have demonstrated a predictive value for second primary carcinoma only for the p53 status of the epithelia but not for the p53 status of the primary tumors. This last argument supports the notion that the second primary tumors can result from events in the epithelia, as postulated by the "field cancerization" concept (27) . Our failure to find a correlation between p53 positivity in tumor-distant epithelia and tumor size and stage, as well as between second primary malignancy and primary tumor size and stage, also supports the alternative concept of field cancerization as a major basis of second primary malignancy in head and neck cancer.

Our results confirm earlier studies that had already revealed some predictive impact of p53 overexpression for malignant transformation (15, 16, 17) . It should be stressed again, however, that our results also agree with the conclusion of another recent study on 21 patients with oral cancer, that p53 overexpression does not necessarily predict further malignant disease (16) , because the positive predictive value of the p53 expression status in tumor-distant epithelia for second primary tumors is moderate. Although the actuarial rate of second primary cancer in our total patient cohort was 14.3%, this rate increased to 28.6% in the p53-positive group (14 of 49 patients were affected), whereas in the p53-negative group, the rate of second primary cancer was only 1.8%. Hence, the difference between the groups regarding risk of second primary cancer was large (odds ratio, 22.0). Because of the very high specificity of p53 overexpression for the mucosa in patients with a malignant tumor and the good sensitivity of mucosal p53 overexpression in relation to second primary cancer, it is a good biomarker for the development of second primary tumors (irrespective of whether this results from field cancerization or by intraepithelial spread).

What is the relationship between p53 overexpression and p53 gene mutation in tumor-distant mucosa, and would the identification of p53 gene mutation in tumor-distant epithelia provide a better predictor for second primary tumor development? Previously, we found p53 gene mutations only in a fraction of the tumor-surrounding epithelia with p53 overexpression (19) . We have preliminary data from DNA sequencing of p53-positive mucosal biopsies from 11 patients, 4 of whom had second primary cancer in the upper aerodigestive tract. Among the latter group, 18 microdissected areas were sequenced. In 5 lesions, including those presented in Fig. 1Citation , b and c, mutations were found, attributable to three of the four patients with second primary cancer (mutation:overexpression ratio, 0.28). The mutational status differed from the primary tumors. In the group of 7 patients without second primary tumor in the upper aerodigestive tract, sequencing 11 p53-positive microdissected areas revealed one mutation (mutation:overexpression ratio, 0.01). It seems notable that this patient experienced a prostate carcinoma as second primary malignancy (data not shown). On the basis of this limited experience, the assumption seems justified that the correlation between p53 mutation and overexpression is generally low in tumor-distant mucosal lesions, and the benefit of mutational analysis would be uncertain. Large-scale mutational analysis of tumor-distant mucosal biopsies as it was performed in the basic studies (19 , 20) , which is very expensive and time consuming, is not feasible for most clinical laboratories and for a large number of cases, whereas immunohistochemical staining using established protocols is easy to set up and gives fast and reliable information. Furthermore, mutational analysis is confronted with the problem that negative results are not conclusive. This is because these lesions are mostly very small (note the PCR-SSCP analyses in Ref. 19 ),4 and it is not clear whether microdissection of undefined mucosal areas will actually catch cells with p53 mutations. Possibly, the new DNA chip technology can be adapted to identify mutations despite a high background of wild-type sequence (28) .

It is also possible that other markers might improve the positive predictive value of p53 overexpression for the individual epithelial lesions. Because cytogenetic alterations are another hallmark of premalignant and malignant transformation and have been found to be correlated with p53 overexpression and mutation (Ref. 29 and references therein), allelic imbalances assessed by microsatellite marker analysis (30) and numerical chromosomal aberrations assessed by fluorescence in situ hybridization (25 , 30, 31, 32, 33) appear particularly promising.

In conclusion, p53 overexpression in tumor-distant epithelia should serve as a biomarker to identify those patients who are at high risk to develop second primary carcinomas. Because patients with locally cured malignant tumors are more likely to die from a second primary carcinoma rather than from the recurrence of the primary tumor itself, this potential biomarker may allow new intervention strategies for those patients.


   ACKNOWLEDGMENTS
 
We are greatly indebted to Antje Schuhmann and Wolfgang Klein-Kühne for excellent technical support. We specifically thank Dr. Christa Flechtenmacher, Institute of Pathology, University of Heidelberg, for histopathological assessment and helpful discussions.


   FOOTNOTES
 
The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked advertisement in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

1 This study was supported by the Wilhelm Sander-Stiftung, the Verein zur Förderung der Krebsforschung in Deutschland e.V., the Tumorzentrum Heidelberg/Mannheim, and the Forschungsförderungsprogramm der Medizinischen Fakultät Heidelberg. Back

2 To whom requests for reprints should be addressed, at HNO-Klinik, Molecular Biology Laboratory, University of Heidelberg, Im Neuenheimerfild 400, D-69120, Heidelberg, Germany. Phone: 49-6221-56-7278; Fax: 06221/564604; E-mail: Franz_Bosch{at}med.uni-heidelberg.de Back

3 The abbreviation used is: SCC, squamous cell carcinoma. Back

4 Unpublished observations. Back

Received 6/12/00; revised 11/20/00; accepted 11/20/00.


   REFERENCES
Top
 ABSTRACT
 INTRODUCTION
 PATIENTS AND METHODS
 RESULTS
 DISCUSSION
 REFERENCES
 

  1. Boring C. C., Squire T. S., Tong T. Cancer statistics.. CA Cancer J. Clin., 42: 18-381, 1992.
  2. Field J. K. Oncogenes and tumour-suppressor genes in squamous cell carcinoma of the head and neck.. Oral Oncol. Eur. J. Cancer, 28B: 67-76, 1992.[CrossRef]
  3. Hollstein M., Sidransky D., Vogelstein B., Harris C. C. p53 mutations in human cancer.. Science (Washington DC), 253: 49-53, 1991.[Abstract/Free Full Text]
  4. Raybaud-Diogene H., Tetu B., Morecy R., Fortin A., Monteil R. A. p53 overexpression in head and neck squamous cell carcinoma: review of the literature.. Oral Oncol. Eur. J. Cancer, 32B: 143-149, 1996.[CrossRef]
  5. Koch W. M., Brennan J. A., Zahurak M., Goodman S. N., Westra W. H., Schwab D., Yoo G. H., Lee D. J., Forastiere A. A., Sidransky D. p53 mutation and locoregional treatment failure in head and neck squamous cell carcinoma.. J. Natl. Cancer Inst., 88: 1580-1586, 1996.[Abstract/Free Full Text]
  6. Brennan J. A., Mao L. M., Hruban R. H., Boyle J. O., Eby Y. J., Koch W. M., Goodman S. N., Sidransky D. Molecular assessment of histopathological staging in squamous cell carcinoma of the head and neck.. N. Engl. J. Med., 332: 429-435, 1995.[Abstract/Free Full Text]
  7. Erber R., Conradt C., Homann N., Enders C., Finckh M., Dietz A., Weidauer H., Bosch F. X. TP53 DNA contact mutations are selectively associated with allelic loss and have a strong clinical impact in head and Neck cancer.. Oncogene, 16: 1671-1679, 1998.[CrossRef][Medline]
  8. Shin D. M., Lee J. S., Lippman S. M., Lee J. J., Tu Z. N., Choi G., Heyne K., Shin H. J., Ro J. Y., Goepfert H., Hong W. K., Hittelman W. N. p53 expression: predicting recurrence and second primary tumors in head and neck squamous cell carcinoma.. J. Natl. Cancer Inst., 88: 519-529, 1996.[Abstract/Free Full Text]
  9. Ahomadegbe J. C., Barrois M., Fogel S., LeBihan M. L., Douc-Rasy S., Duvillard P., Armand J. P., Riou G. High incidence of p53 alterations (mutation, deletion, overexpression) in head and neck primary tumors and metastases: absence of correlation with clinical outcome.. Frequent protein overexpression in normal epithelium and in early non-invasive lesions. Oncogene, 10: 1217-1227, 1995.[Medline]
  10. Gasparini G., Weidner N., Maluta S., Pozza F., Boracchi P., Mezzetti M., Testolin A., Bevilacqua P. Intratumoral microvessel density and p53 protein: correlation with metastasis in head and neck squamous carcinoma.. Int. J. Cancer, 55: 739-744, 1993.[Medline]
  11. Maestro R., Dolcetti R., Gasparotto D., Dolglioni C., Pelucchi S., Barzan L., Grandi E., Boiocchi M. High frequency of p53 gene alterations associated with protein overexpression in human squamous cell carcinoma of the larynx.. Oncogene, 7: 1159-1166, 1992.[Medline]
  12. Nylander K., Stenling R., Gustafsson H., Zackrisson B., Roos G. p53 expression and cell proliferation in squamous cell carcinomas of the head and neck.. Cancer (Phila.), 75: 87-93, 1995.[CrossRef][Medline]
  13. Sauter E. R., Ridge J. A., Gordon J., Eisenberg B. L. p53 overexpression correlates with increased survival in patients with squamous carcinoma of the tongue base.. Am. J. Surg., 164: 651-653, 1992.[CrossRef][Medline]
  14. Ogden G. R., Kiddie R. A., Lunny D. P., Lane D. P. Assessment of p53 expression in normal, benign, and malignant oral mucosa.. J. Pathol., 166: 389-394, 1992.[CrossRef][Medline]
  15. Uhlmann D. L., Adams G., Knapp D., Aeppli D. M., Nihans G. Immunohistochemical staining for markers of future neoplastic progression in the larynx.. Cancer Res., 56: 2199-2205, 1996.[Abstract/Free Full Text]
  16. Gallo O., Santucci M., Franchi A. Cumulative prognostic value of p16/CDKN 2 and p53 oncoprotein expression in premalignant laryngeal lesions.. J. Natl. Cancer Inst., 89: 1161-1163, 1997.[Free Full Text]
  17. Ogden G. R., Chisholm D. M., Morris H. M., Stevenson J. H. Overexpression of p53 in normal oral mucosa of oral cancer patients does not necessarily predict further malignant disease.. J. Pathol., 182: 180-184, 1997.[CrossRef][Medline]
  18. Warnakulasuriya S. Lack of molecular markers to predict malignant potential of oral precancer.. J. Pathol., 190: 407-409, 2000.[CrossRef][Medline]
  19. Nees M., Homann N., Discher H., Andl T., Enders C., Schuhmann A., Bosch F. X. Expression of mutated p53 occurs in tumor-distant epithelia of head and neck cancer patients: a possible molecular basis for the development of multiple tumors.. Cancer Res., 53: 4189-4196, 1993.[Abstract/Free Full Text]
  20. Waridel F., Estreicher A., Bron L., Flaman J. M., Fontolliet C., Monnier P., Frebourg T., Iggo R. Field cancerisation and polyclonal p53 mutation in the upper aero-digestive tract.. Oncogene, 14: 163-169, 1997.[CrossRef][Medline]
  21. Jones A. S., Morar P., Phillips D. E., Field J. K., Husband D., Helliwell T. R. Second primary tumors in patients with head and neck squamous cell carcinoma.. Cancer (Phila.), 75: 1343-1352, 1995.[CrossRef][Medline]
  22. Cruz I. B., Snijders P. J. F., Meijjer C. J., Braakhuis B. J., Snow G. B., Walboomers J. M., van der Waal J. p53 expression above the basal layer in oral mucosa is an early event of malignant transformation and has predictive value for developing oral squamous cell carcinoma.. J. Pathol., 184: 360-368, 1998.[CrossRef][Medline]
  23. Dowell S. P., Ogden G. R. The use of antigen retrieval for immunohistochemical detection of p53 overexpression in malignant and benign oral mucosa: a cautionary note.. J. Oral Pathol. Med., 25: 60-64, 1996.[CrossRef][Medline]
  24. van Oijen M. G. C. T., van de Craats J. G., Slootweg P. J. p53 overexpression in oral mucosa in relation to smoking.. J. Pathol., 187: 469-474, 1999.[CrossRef][Medline]
  25. Chung K. Y., Mukhopadhyay T., Kim J., Casson A., Ro J. Y., Goepfert H., Hong W. K., Roth J. A. Discordant p53 gene mutations in primary head and neck cancers and corresponding second primary cancers of the upper aerodigestive tract.. Cancer Res., 53: 1676-1683, 1993.[Abstract/Free Full Text]
  26. van Oijen M. G. C. T., Leppers vd Straat F. G. J., Tilanus M. G. J., Slootweg P. J. The origins of multiple squamous cell carcinomas in the aerodigestive tract.. Cancer (Phila.), 88: 884-893, 2000.[CrossRef][Medline]
  27. Slaughter D. P., Southwick H. W., Smejkal W. "Field cancerisation" in oral stratified squamous epithelium.. Cancer (Phila.), 6: 963-968, 1953.[CrossRef][Medline]
  28. Ahrendt S. A., Halachmi S., Chow J. T., Wu L., Halachmi N., Yang S. C., Wehage S., Jen J., Sidransky D. Rapid p53 sequence analysis using an oligonucleotide probe array in primary lung cancer.. Proc. Natl. Acad. Sci. USA, 96: 7382-7389, 1999.[Abstract/Free Full Text]
  29. Soder A. I., Hopman A. H. N., Ramaekers F. C. S., Conradt C., Bosch F. X. Distinct non-random patterns of chromosomal aberrations in the progression of squamous cell carcinomas of the head and neck.. Cancer Res., 55: 5030-5037, 1995.[Abstract/Free Full Text]
  30. Mao L., Lee J. S., Fan Y. H., Ro J. Y., Batsakis J. G., Lippman S., Hittelman W., Hong W. K. Frequent microsatellite alterations at chromosomes 9p21 and 3p14 in oral premalignant lesions and their value in cancer risk assessment.. Nat. Med., 2: 682-685, 1996.[CrossRef][Medline]
  31. Voravud N., Shin D. M., Ro J. Y., Lee J. S., Hong W. K., Hittelman W. N. Increased polysomies of chromosome 7 and 17 during head and neck multistage tumorigenesis.. Cancer Res., 3: 2874-2883, 1993.
  32. Lee J. S., Kim S. Y., Hong W. K., Lippman S. M., Ro J. Y., Gay M. L., Hittelman W. N. Detection of chromosomal polysomy in oral leukoplakia, a premalignant lesion.. J. Natl. Cancer Inst., 23: 1951-1954, 1993.
  33. Lenz C. F., Pfuhl A., Finckh M., Weidauer H., Bosch F. X. Oral leukoplakias show numerical chromosomal aberrations detected by FISH.. Laryngoscope, 108: 917-921, 1998.[CrossRef][Medline]



This article has been cited by other articles:


Home page
 Cancer Epidemiol. Biomarkers Prev.Home page
V. G. Vogel
Identifying and Screening Patients at Risk of Second Cancers
Cancer Epidemiol. Biomarkers Prev., November 1, 2006; 15(11): 2027 - 2032.
[Abstract] [Full Text] [PDF]

This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Homann, N.
Right arrow Articles by Bosch, F. X.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Homann, N.
Right arrow Articles by Bosch, F. X.

HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online